title: Mergers and innovation in the pharmaceutical industry.
abstract: Conflicting trends confound the pharmaceutical industry. The productivity of pharmaceutical innovation has declined in recent years. At the same time, the cohort of large companies who are the leading engines of pharmaceutical R&D has become increasingly concentrated. The concurrent presence of these trends is not sufficient to determine causation. In response to lagging innovation prospects, some companies have sought refuge in mergers and acquisitions to disguise their dwindling prospects or gain R&D synergies. On the other hand, the increased concentration brought on by recent mergers may have contributed to the declining rate of innovation. In this paper, we consider the second of these causal relationships: the likely impact of the recent merger wave among the largest pharmaceutical companies on the rate of innovation. In other words, have recent mergers, which may have been taken in response to lagging innovation, represented a self-defeating strategy that only made industry outcomes worse?
authors.affiliation: University of California, Los Angeles, Santa Barbara, USA. comanor@ucla.edu
authors.forename: William S
authors.initials: WS
authors.lastname: Comanor
authors.forename: F M
authors.initials: FM
authors.lastname: Scherer
mesh_terms: D035843:Biomedical Research / Q000191:economics / Q000706:statistics & numerical data; D055808:Drug Discovery / Q000191:economics / Q000458:organization & administration*; D004345:Drug Industry / Q000191:economics / Q000458:organization & administration*; D004526:Efficiency; D017598:Efficiency, Organizational